Drug
Lurasidone
Lurasidone: highest development phase Post-Market, developed by Sumitomo Pharma. 5 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Sumitomo Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| Lurasidone NCT01569659 | Post-Market | Schizophrenia |
| Lurasidone NCT01421134 | Phase 3 | Major Depressive Disorder With Mixed Features |
| lurasidone NCT00868959 | Phase 3 | Bipolar Depression |
| Lurasidone 20 mg NCT00044005 | Phase 2 | Schizophrenia |
| Lurasidone HCl NCT01082250 | Phase 1 | Schizophrenia |
Latest
No recent events.
Follow Lurasidone on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.